ENTA
Enanta Pharmaceuticals, Inc.
$11.64
+0.17%
2026-10-23
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Key Fundamentals
Forward P/E
-5.00
EPS (TTM)
$-2.42
ROE
-70.1%
Revenue Growth (YoY)
-21.6%
Profit Margin
-96.9%
Debt/Equity
180.12
Price/Book
3.42
Beta
0.94
Market Cap
$346.0M
Avg Volume (10D)
262K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$15.05
60D Low
$10.95
Avg Volume
243K
Latest Close
$11.64
Get breakout alerts for ENTA
Sign up for Breakout Scanner to receive daily notifications when ENTA triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Enanta Pharmaceuticals, Inc. (ENTA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ENTA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ENTA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.